Aerpio Pharmaceuticals, Inc. (NYSE:ARPO) has received an average broker rating score of 2.33 (Buy) from the three brokers that provide coverage for the stock, Zacks Investment Research reports. Two investment analysts have rated the stock with a hold recommendation and one has assigned a strong buy recommendation to the company. Aerpio Pharmaceuticals’ rating score has declined by 3.6% in the last 90 days as a result of various analysts’ ratings changes.

Brokers have set a 12 month consensus price objective of $4.67 for the company and are predicting that the company will post ($0.12) earnings per share for the current quarter, according to Zacks. Zacks has also given Aerpio Pharmaceuticals an industry rank of 48 out of 256 based on the ratings given to its competitors.

Separately, HC Wainwright restated a “neutral” rating on shares of Aerpio Pharmaceuticals in a report on Wednesday, June 12th.

Shares of ARPO traded down $0.03 during mid-day trading on Tuesday, reaching $0.78. The company’s stock had a trading volume of 113,762 shares, compared to its average volume of 336,059. Aerpio Pharmaceuticals has a 52 week low of $0.75 and a 52 week high of $4.25. The stock’s fifty day moving average price is $0.89.

Aerpio Pharmaceuticals (NYSE:ARPO) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.21) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.20) by ($0.01).

About Aerpio Pharmaceuticals

Aerpio Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy.

See Also: Candlestick

Get a free copy of the Zacks research report on Aerpio Pharmaceuticals (ARPO)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Aerpio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerpio Pharmaceuticals and related companies with's FREE daily email newsletter.